| NBDF

NBDF News Mention: Sad News of a Mother Charged in Death of 3-Year-Old Chelsea Boy with Hemophilia

Read more about NBDF News Mention: Sad News of a Mother Charged in Death of 3-Year-Old Chelsea Boy with Hemophilia

Data provided by the National Bleeding Disorders Foundation (NBDF) was referenced recently in the coverage of a tragic case in Chelsea that took a dark turn for 3-year-old Yael Guardado Prudencio, a child with hemophilia and a seizure disorder.

Take the HTC Patient Satisfaction Survey

Read more about Take the HTC Patient Satisfaction Survey

PSS input from affected individuals and families help HTCs identify areas where they may have strengths and where they can improve.

Rebinyn Supplies Restored in 3,000 IU Vial Size

Read more about Rebinyn Supplies Restored in 3,000 IU Vial Size

Rebinyn is a recombinant factor IX extended half-life therapy for the treatment of hemophilia B.

Hemophilia B Therapy FDA Approved for Expanded Indication

Read more about Hemophilia B Therapy FDA Approved for Expanded Indication

The new indication is based on a phase 3/4 clinical trial in of patients under 12 years of age with severe or moderately severe hemophilia B.

NBDF Celebrates Five Years of Community Voices in Research

Read more about NBDF Celebrates Five Years of Community Voices in Research

For Immediate Release
CONTACT:
Carrie Strehlau and Kyla Clark
National Bleeding Disorders Foundation
212-382-3773
kclark@hemophilia.org

March HANDI Highlights Now Available!

Read more about March HANDI Highlights Now Available!

NBDF is pleased to announce HANDI Highlights, which is designed to connect the bleeding disorders community with timely, practical, and readily-accessible resources.